Valuation: BeOne Medicines AG

Capitalization 3.46TCr 2.95TCr 2.7TCr 2.56TCr 4.73TCr 3,23800Cr 4.84TCr 32TCr 12TCr 1,55500Cr 13TCr 13TCr 5,52100Cr P/E ratio 2026 *
56.4x
P/E ratio 2027 * 33.8x
Enterprise value 3.12TCr 2.66TCr 2.43TCr 2.31TCr 4.26TCr 2,91500Cr 4.36TCr 29TCr 11TCr 1,40000Cr 12TCr 11TCr 4,97000Cr EV / Sales 2026 *
4.88x
EV / Sales 2027 * 4.14x
Free-Float
96.17%
Yield 2026 *
-
Yield 2027 * -
1 day-1.81%
1 week+2.18%
Current month+5.17%
1 month+13.45%
3 months-6.57%
6 months-1.97%
Current year+2.80%
1 week 311.25
Extreme 311.25
328.39
1 month 271.47
Extreme 271.4701
328.39
Current year 271.47
Extreme 271.4701
372.73
1 year 218.31
Extreme 218.31
385.22
3 years 126.97
Extreme 126.9681
385.22
5 years 118.18
Extreme 118.18
426.56
10 years 24.53
Extreme 24.53
426.56
Manager TitleAgeSince
Chief Executive Officer 57 28/10/2010
Director of Finance/CFO 50 22/07/2024
President 64 01/04/2018
Director TitleAgeSince
Chairman 57 27/01/2016
Director/Board Member 51 01/04/2015
Director/Board Member 52 01/10/2014
Change 5d. change 1-year change 3-years change Capi.($)
-1.81%+2.18%+35.21%+20.93% 3.53TCr
-2.85%-1.16%-5.23%-10.26% 4.72TCr
+1.83%+9.24%+305.06%+509.50% 3.08TCr
-0.61%+2.15%+22.08%-11.53% 2.97TCr
-1.22%+4.00%+34.13%+32.03% 2.93TCr
-2.07%-3.82%+49.11%+196.91% 1.52TCr
-2.56%+2.73%+73.79%+173.49% 1.51TCr
-0.26%+6.87%+39.92%+15.29% 1.44TCr
+1.07%-11.91%+3,606.12%+3,880.94% 1.39TCr
-0.12%-0.23%+163.31%+106.97% 1.24TCr
Average -0.86%+1.74%+432.35%+491.43% 2.43TCr
Weighted average by Cap. -1.05%+2.52%+273.85%+319.09%

Financials

2026 *2027 *
Net sales 638.77Cr 544.12Cr 498.79Cr 473.05Cr 872.77Cr 60TCr 893.06Cr 5.86TCr 2.3TCr 29TCr 2.4TCr 2.35TCr 1,01800Cr 734.82Cr 625.94Cr 573.79Cr 544.18Cr 1TCr 69TCr 1.03TCr 6.75TCr 2.65TCr 33TCr 2.76TCr 2.7TCr 1,17100Cr
Net income 65Cr 55Cr 50Cr 48Cr 88Cr 6.04TCr 90Cr 593Cr 232.92Cr 2.9TCr 242.26Cr 237.26Cr 10TCr 105.06Cr 89Cr 82Cr 78Cr 143.55Cr 9.82TCr 146.89Cr 964.52Cr 378.84Cr 4.72TCr 394.03Cr 385.9Cr 17TCr
Net Debt -345.61Cr -294.4Cr -269.87Cr -255.94Cr -472.21Cr -32TCr -483.19Cr -3.17TCr -1.25TCr -16TCr -1.3TCr -1.27TCr -55TCr -421.87Cr -359.36Cr -329.42Cr -312.42Cr -576.41Cr -39TCr -589.81Cr -3.87TCr -1.52TCr -19TCr -1.58TCr -1.55TCr -67TCr
Logo BeOne Medicines AG
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.
Employees
12,000
Date Price Change Volume
21/26/21 312.31 $ -1.81% 1,89,085
20/26/20 318.07 $ -1.79% 1,59,375
17/26/17 323.87 $ +0.99% 2,07,225
16/26/16 320.70 $ +0.24% 2,06,871
15/26/15 319.94 $ +3.21% 1,96,136
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
26
Last Close Price
312.31USD
Average target price
408.20USD
Spread / Average Target
+30.70%

Quarterly revenue - Rate of surprise